Tesla claims to have launched a robotaxi service in Dallas and Houston over the weekend, but so far, online crowdsourcing tools indicate that very few cars are actually available. On Saturday, @TeslaRobotaxi posted a 14-second video of a Model Y vehicle driving without any human safety monitor in the front seats . Elon Musk re-posted the video, adding, "Try Tesla Robotaxi in Dallas & Houston!" Try...
Tesla claims to have launched a robotaxi service in Dallas and Houston over the weekend, but so far, online crowdsourcing tools indicate that very few cars are actually available. On Saturday, @TeslaRobotaxi posted a 14-second video of a Model Y vehicle driving without any human safety monitor in the front seats . Elon Musk re-posted the video, adding, "Try Tesla Robotaxi in Dallas & Houston!" Try Tesla Robotaxi in Dallas & Houston! https://t.co/K6Ss0S7v4k - Elon Musk (@elonmusk) April 18, 2026 But as of Sunday evening, the service appeared to be largely unavailable, according to Robotaxi Tracker , an online data site that tracks autonom … Read the full story at The Verge.
The post This Under-$1 Pre-IPO AI Stock is Up 4,000% Already, And It’s Still Open to Retail Investors by Benzinga Contributors appeared first on Benzinga . Visit Benzinga to get more great content like this. By the time most investors hear about a company, it’s already public and priced like it. Immersed is different. It’s a pre-IPO, private company operating at the intersection of AI, Spatial Com...
The post This Under-$1 Pre-IPO AI Stock is Up 4,000% Already, And It’s Still Open to Retail Investors by Benzinga Contributors appeared first on Benzinga . Visit Benzinga to get more great content like this. By the time most investors hear about a company, it’s already public and priced like it. Immersed is different. It’s a pre-IPO, private company operating at the intersection of AI, Spatial Computing, and productivity, with more than 1.5M users already working up to 60 hours per week (the equivalent of 2,000 cumulative years) inside its platform. That usage matters because Immersed is not selling an idea. It’s building the full next-gen computing stack that combines software, hardware, and AI, anchored in real user behavior. Major technology partners include Meta, Samsung, and Qualcomm. The company has also reserved a NASDAQ ticker ($IMRS) and is currently allowing new Pre-IPO investors in at $0.72 per share, but that window won’t stay open forever. Early investors include Tim Tebow and executives from Facebook, Reddit, Intel, and SailPoint. Don’t miss the chance to join them before a potential IPO. Investors can earn up to 20% bonus shares, depending on investment size. An investment opportunity you don’t want to miss Immersed changed the game in Spatial Computing (AR/VR), developing the Meta Quest store’s most-used AR/VR productivity app. They develop enterprise-grade software that enables professionals and teams to work full-time in shared virtual environments using AR/VR, supporting multiple virtual displays, real-time collaboration, and seamless integration across macOS, Windows, and Linux. But that’s not all. Immersed’s soon-to-be-released XR headset, Visor in partnership with Qualcomm, has 2M more pixels than Apple’s Vision Pro for 70% less cost and 70% less weight. No wonder they’ve raised $28M+ to-date, and are projecting $71M in first-year sales. Here’s how they’re redefining the $250B+ future of work: Breakthrough Platform: Immersed built the first ful...
FangXiaNuo/E+ via Getty Images Overview I'm revisiting Adaptive Biotechnologies Corporation ( ADPT ) today. This is a company I've now covered for over two years. They sell products in the minimal residual disease [MRD] market, which is very competitive, but as I noted in my last analysis , the company's momentum here is undeniable. I conducted a discounted cash flow analysis as well, and I determ...
FangXiaNuo/E+ via Getty Images Overview I'm revisiting Adaptive Biotechnologies Corporation ( ADPT ) today. This is a company I've now covered for over two years. They sell products in the minimal residual disease [MRD] market, which is very competitive, but as I noted in my last analysis , the company's momentum here is undeniable. I conducted a discounted cash flow analysis as well, and I determined that the stock appeared priced for 30% CAGR and 17% free cash flow margin, which reflects pretty high expectations. My report followed Adaptive's Q3 earnings, where its MRD segment jumped 52% Y/Y to $56.8 million. Management at this time was stressing that its MRD segment as a standalone was cash flow positive in Q3. Looking ahead to Q4, it was clear that management was trying to manage some expectations regarding sequential momentum due to seasonality. And it was interesting that management acknowledged emerging competition within DLBCL, which is an important submarket within MRD. So I thought that 2026 looked like a “prove-it” year for Adaptive. While it was obvious that the company had established a good niche in the MRD market, the duration of cash flows was, in my view, a major uncertainty. So I've been at a “Hold” rating on Adaptive’s stock. Below, I take a closer look at its 2025 performance and what the company expects for this year. Recent Developments Starting with earnings , Adaptive did not disappoint in Q4. It generated $71.7 million in revenue, which was a $10.7 million beat. And represented 51% Y/Y growth. Again, its MRD segment was the primary growth driver, generating $61.9 million in revenue in Q4 alone and $212 million in 2025. The company is still seeing robust volume for its clonoSEQ product. And the U.S. clinical average selling price was $1,307 for the year, which was up 17% Y/Y, and exited Q4 around $1,350. The company's long-term target is $1,700+. Author's Compilation MRD achieved positive adjusted EBITDA and positive cash flow for the full ye...
Nvidia's modeled Fair Value price target edges from US$268.22 to US$268.61, a small move that still matters if you are trying to understand how sentiment around the stock is shifting. That tweak sits inside a broader debate on Wall Street, where some analysts lean into Nvidia's AI data center order visibility and product roadmap, while others question how much of the 2026 AI demand story is alread...
Nvidia's modeled Fair Value price target edges from US$268.22 to US$268.61, a small move that still matters if you are trying to understand how sentiment around the stock is shifting. That tweak sits inside a broader debate on Wall Street, where some analysts lean into Nvidia's AI data center order visibility and product roadmap, while others question how much of the 2026 AI demand story is already reflected in valuation. As you read on, you will see how to track these evolving calls and what...
Advanced Micro Devices (NASDAQ:AMD) stock just earned a strong endorsement from Stifel, which raised its price target to $320 from $280 while maintaining a Buy rating on the shares. The move signals growing Wall Street conviction that AI infrastructure demand isn’t slowing down anytime soon. For long-term investors, that’s a meaningful statement about where the ... Stifel Raises AMD Target to $320...
Advanced Micro Devices (NASDAQ:AMD) stock just earned a strong endorsement from Stifel, which raised its price target to $320 from $280 while maintaining a Buy rating on the shares. The move signals growing Wall Street conviction that AI infrastructure demand isn’t slowing down anytime soon. For long-term investors, that’s a meaningful statement about where the ... Stifel Raises AMD Target to $320: Is the AI Chip Rally Just Getting Started?
The Hong Kong Securities and Futures Commission. Photo: IC Hong Kong has introduced a regulatory framework allowing licensed virtual-asset trading platforms to offer secondary-market trading for authorized tokenized open-ended funds. The initiative will initially cover money market funds and could gradually expand to all tokenized funds authorized by the Securities and Futures Commission (SFC) if ...
The Hong Kong Securities and Futures Commission. Photo: IC Hong Kong has introduced a regulatory framework allowing licensed virtual-asset trading platforms to offer secondary-market trading for authorized tokenized open-ended funds. The initiative will initially cover money market funds and could gradually expand to all tokenized funds authorized by the Securities and Futures Commission (SFC) if the rollout proves successful.
Yahoo Finance's Julie Hyman and Brooke DiPalma takes a closer look at some of Monday morning's trending tickers and stories. Marvell (MRVL) stock is surging on reports that the company is in talks with Google (GOOG, GOOGL) to develop artificial intelligence (AI) chips. AST SpaceMobile (ASTS) stock is falling after one of its satellites faced a setback. Shares of companies involved in medical psych...
Yahoo Finance's Julie Hyman and Brooke DiPalma takes a closer look at some of Monday morning's trending tickers and stories. Marvell (MRVL) stock is surging on reports that the company is in talks with Google (GOOG, GOOGL) to develop artificial intelligence (AI) chips. AST SpaceMobile (ASTS) stock is falling after one of its satellites faced a setback. Shares of companies involved in medical psychedelic drugs, including Compass (CMPS), ATAI (ATAI), and GH Research (GHRS), are skyrocketing after President Trump signed an executive order to expedite psychedelic research.
Hong Kong travellers in Japan were reported safe by at least one major tour operator while the Immigration Department said it was closely monitoring the situation after a powerful earthquake struck off the country’s northeast coast on Monday, triggering tsunami warnings. Steve Huen Kwok-chuen, executive director of EGL Tours, said the operator currently had about 40 tour groups in Japan, including...
Hong Kong travellers in Japan were reported safe by at least one major tour operator while the Immigration Department said it was closely monitoring the situation after a powerful earthquake struck off the country’s northeast coast on Monday, triggering tsunami warnings. Steve Huen Kwok-chuen, executive director of EGL Tours, said the operator currently had about 40 tour groups in Japan, including three in the northeast and four in Hokkaido, areas covered by the alert. “All our customers are...
PM Images/DigitalVision via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the consumer staples sector. Below is a list of the top 10 consumer staples stocks ranked by their RSI. The list includes companies from diverse industries within the sector, ranging from food distributors to personal care products. The list is topped by United...
PM Images/DigitalVision via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the consumer staples sector. Below is a list of the top 10 consumer staples stocks ranked by their RSI. The list includes companies from diverse industries within the sector, ranging from food distributors to personal care products. The list is topped by United Natural Foods ( UNFI ), with an RSI of 69. Smithfield Foods ( SFD ), Interparfums ( IPAR ), and Target Corporation ( TGT ) follow closely behind, each with an RSI of 66. Casey’s General Stores ( CASY ) rounds out the top five with an RSI of 65. Other notable entries include Performance Food Group Company ( PFGC ), PriceSmart ( PSMT ), and Central Garden & Pet Company ( CENT ). The RSI values for this top 10 list range from 69 down to 62, with Brown-Forman Corporation ( BF.B ) and Coty Inc. ( COTY ) each posting an RSI of 62. The Relative Strength Index is a momentum oscillator that measures the velocity and magnitude of price changes, plotting them on a scale from 0 to 100. RSI compares the magnitude of recent gains to recent losses over a chosen lookback period, typically 14 days. Here is the list: United Natural Foods, Inc. ( UNFI ), RSI: 69 Smithfield Foods, Inc. ( SFD ), RSI: 66 Interparfums, Inc. ( IPAR ), RSI: 66 Target Corporation ( TGT ), RSI: 66 Casey’s General Stores, Inc. ( CASY ), RSI: 65 Performance Food Group Company ( PFGC ), RSI: 64 PriceSmart, Inc. ( PSMT ), RSI: 63 Central Garden & Pet Company ( CENT ), RSI: 63 Brown-Forman Corporation ( BF.B ), RSI: 62 Coty Inc. ( COTY ), RSI: 62 Consumer Staples ETFs: ( XLP ), ( VDC ), ( IYK ), ( FSTA ), ( KXI ), and ( RSPS ) More on Consumer Staples stocks RSPS: Consumer Staples Dashboard For April Finding The Opportunities After The Selloff And End Of The War KXI: Consumer Staples Dashboard For March Beverage sector profitability rankings: Coca-Cola and PepsiCo lead the pack PepsiCo beats Q1 estimates, ranks second on...
Claims system launches months after supreme court ruled Trump had no legal authority to impose tariffs Sign up for the Breaking News US email to get newsletter alerts in your inbox The Trump administration began on Monday accepting applications from businesses seeking refunds for more than $166bn in tariffs, months after the supreme court ruled that the president had no legal authority to impose t...
Claims system launches months after supreme court ruled Trump had no legal authority to impose tariffs Sign up for the Breaking News US email to get newsletter alerts in your inbox The Trump administration began on Monday accepting applications from businesses seeking refunds for more than $166bn in tariffs, months after the supreme court ruled that the president had no legal authority to impose them. The administration launched on Monday the digital claims system , named Cape, which they said in court filings could handle about 63% of affected import filings, with the remainder to follow. Continue reading...
franckreporter/iStock via Getty Images Cantor Fitzgerald remains bullish on equities ( SPY ) ( DIA ) ( QQQ ) in a note released Monday, citing rising earnings growth rates and estimates, sharply lower valuations and significantly reduced institutional positioning. The firm also expects second-half rate cuts and believes the economy can weather current oil price pressures even if elevated prices pe...
franckreporter/iStock via Getty Images Cantor Fitzgerald remains bullish on equities ( SPY ) ( DIA ) ( QQQ ) in a note released Monday, citing rising earnings growth rates and estimates, sharply lower valuations and significantly reduced institutional positioning. The firm also expects second-half rate cuts and believes the economy can weather current oil price pressures even if elevated prices persist. The note addresses four key concerns that had weighed on markets before recent geopolitical tensions: private credit ( BIZD ) ( PRIV ) ( PCR ) ( VPC ) risks, artificial intelligence ( AIQ ) ( AIEQ ) data center overbuilding, AI’s potential impact on jobs and software ( IGV ) ( IGPT ) companies, and valuation levels. According to Cantor analyst Eric Johnston, most of these worries have diminished. Private credit fears, initially driven by duration mismatches and withdrawal halts at some funds, have eased as analysis suggests losses will likely not pose systemic risks. Concerns about AI data center overbuilding are dissipating as Anthropic ( ANTHRO ) reports surging numbers while compute capacity remains constrained. Valuations have also fallen to more attractive levels. Johnston noted that while an Iran deal remains unsigned and short-term risks persist, significant drawdown risk has been greatly reduced. However, one concern remains unresolved: the potential for future AI-related job losses. The analyst acknowledged uncertainty about both the magnitude and pace of how this dynamic might unfold. More on the Markets S&P 500: Euphoric Hormuz Crash In The Making And Oil Surge Market Lesson: Why Panic Is A Costly Mistake The War Is Not Over Hormuz disruption lingers: Markets price gradual reopening, not a quick fix Iran war isn't stopping earnings upgrades - Goldman
JHVEPhoto/iStock Editorial via Getty Images In July 2025, I published my first and only article about American life science and clinical research company Thermo Fisher Scientific Inc. ( TMO ). I rated the stock as a “Hold” and wrote in my conclusion: Thermo Fisher is certainly a great business with a wide economic moat around its business. However, I see the stock as fairly valued at best, as I do...
JHVEPhoto/iStock Editorial via Getty Images In July 2025, I published my first and only article about American life science and clinical research company Thermo Fisher Scientific Inc. ( TMO ). I rated the stock as a “Hold” and wrote in my conclusion: Thermo Fisher is certainly a great business with a wide economic moat around its business. However, I see the stock as fairly valued at best, as I don’t see the company growing in the double digits in the years to come. In the last ten years, the acquisition contributed to growth but due to rather high debt levels and very high amounts of goodwill on the balance sheet, I don’t know if Thermo Fisher can continue this strategy. Therefore, I rather see growth rates in the high single digits being reasonable and the stock will remain on my watchlist – together with Waters Corp and Danaher Corporation. Despite my “Hold” rating and rather cautious stance, the stock increased slightly above 20% in value and clearly outperformed the S&P 500. In the meantime, the stock increased even 50% to $643 and came close to its all-time high once again before the correction drove the stock down again (in line with many other stocks around the world). In the following article, I will look at Thermo Fisher again before the company will report its first quarter results on April 23, 2026. And while we can argue that Thermo Fisher will perform stably in the coming quarters and economic uncertainty probably won’t have a huge impact on the business, I still consider the stock price too expensive at this point. Results Fiscal 2025 Let’s start by looking at the full-year results. Total revenue increased from $42,879 million in fiscal 2024 to $44,556 million in fiscal 2025, resulting in 3.9% year-over-year growth for the top line. Operating income increased 5.6% year-over-year from $7,337 million in the previous year to $7,746 million in fiscal 2025. Diluted earnings per share also increased from $16.53 in fiscal 2024 to $17.74 in fiscal 2025, resul...